Received: 29 November 2021
Accepted: 21 January 2022
First Online: 2 February 2022
: This study has been approved by the Regional Committee of Research, Health Region Southeast, Oslo, Norway, at August 24, 2017 (Ref. 2017/681). The ClinicalTrials.gov identifier 20/11/12 prospectively for the Philos Group is NCT01737060 and for the ALPS group 11/03/20 retrospectively is NCT04622852. ExternalRef removed.
: Written consent was obtained from the patients.
: The authors declare that they have no funding or any competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Last author TF attended an instructional course November 28.-29. 2016 arranged by Zimmer Biomet institute.